Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-nodal antibodies - TaiRx US

Next Previous
Drug Profile

Research programme: anti-nodal antibodies - TaiRx US

Alternative Names: Anti-nodal monoclonal antibody diagnostics - TaiRx US; Anti-nodal monoclonal antibody therapeutics- TaiRx US; TRX NOC

Latest Information Update: 28 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ann & Robert H. Lurie Childrens Hospital of Chicago; Northwestern University Feinberg School of Medicine
  • Developer TaiRx US
  • Class Antineoplastics; Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 28 Nov 2022 No recent reports of development identified for research development in Cancer(Diagnosis) in USA (Parenteral)
  • 22 Oct 2018 TaiRx forms a joint venture company, TaiRx US, with BioHealth Innovation for development of anti-nodal antibodies for the treatment and diagnosis of Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top